# Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

> **NCT06742515** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 20 (estimated)

## Conditions studied

- Precursor B-Cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab plus Reduced-dose Chemotherapy

## Key facts

- **NCT ID:** NCT06742515
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-17
- **Primary completion:** 2026-10-01
- **Final completion:** 2028-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742515, "Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06742515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*